Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

First- and Second-Generation Antipsychotics for Children and Young Adults

Slide: 7 of 43

Antipsychotics Approved for Pediatric Use: First-Generation Antipsychotics

  • Chlorpromazine is approved for treatment of schizophrenia, bipolar disorder (mania), severe behavioral problems, and hyperactivity for children from 1 to 12 years old.
  • Droperidol is approved for treatment of agitation in children, but the age group is not specified.
  • Loxapine is approved for treatment of schizophrenia in children aged 12 years and older.
  • Perphenazine is approved for treatment of schizophrenia in children aged 12 years and older.
  • Pimozide is approved for treatment of Tourette’s syndrome in children aged 12 years and older.
  • Prochlorperazine is approved for treatment of schizophrenia in children over 2 years of age and greater than 20 pounds in weight.
  • Thiothixene is approved for treatment of schizophrenia in children aged 12 years and older.
  • Thioridazine is approved for treatment of schizophrenia in children, with no age group specified.
  • Trifluoperazine is approved for treatment of schizophrenia in children aged 6 years and older.